Form 4: Amylyx CFO Plans Future Share Sale for Tax

Amylyx Pharmaceuticals' CFO, James M. Frates, has filed a plan to sell 7,909 shares of common stock on March 2, 2026, to cover tax withholding obligations.

Summary

• James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX), has filed a plan to sell 7,909 shares of common stock.
• The planned sale is scheduled for March 2, 2026, at a weighted average price of $14.5216 per share.
• This transaction is part of a pre-arranged 10b5-1 plan and is intended to satisfy tax withholding obligations associated with the vesting of restricted stock units, making it non-discretionary.
• Following the planned sale, Mr. Frates is expected to directly own 165,638 shares and indirectly own 126,531 shares through various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The planned sale is non-discretionary and for tax purposes, pre-arranged under a 10b5-1 plan, which is a routine occurrence for executives receiving equity compensation, and does not indicate a change in management's outlook on the company.

Positives

• The planned sale is non-discretionary, indicating it is not a voluntary divestment based on a negative outlook.
• The transaction is a routine event related to compensation structure and pre-arranged under a 10b5-1 plan.

Negatives

• A planned reduction in direct insider ownership, even if for tax purposes, will occur.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing beyond the planned transaction.

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes, especially when pre-arranged under a 10b5-1 plan, are common across all industries for executives compensated with restricted stock units. This transaction does not reflect a change in the company's operational or strategic direction.

Comparison to Industry Standards

• This type of non-discretionary sale for tax purposes, pre-arranged under a 10b5-1 plan, is a standard practice for executives receiving equity compensation across various industries.
• It is not comparable to discretionary sales by insiders that might signal a change in confidence or company outlook, nor does it relate to specific project results or company performance benchmarks.

Related Party Transactions

• Shares are held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant.
• Shares are held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant.
• Shares are held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee.

Stakeholder Impact

• Shareholders: Minimal impact as the planned sale is non-discretionary for tax purposes and does not signal a change in company fundamentals or management confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Key Dates

Recommendation

This Form 4 filing details a pre-planned, non-discretionary sale of shares by the CFO to cover tax obligations related to restricted stock unit vesting, executed under a 10b5-1 plan. Such transactions are common and do not typically reflect a change in the executive's confidence in the company or its future prospects. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this report.

Keywords

Amylyx Pharmaceuticals, AMLX, Insider Trading, Form 4, James M. Frates, CFO, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan